Multi-database analysis of BRCA1 and GATA3 reveals distinct molecular features and prognostic significance in breast cancer

Abstract

BRCA1 and GATA3 are critically involved in mammary gland development and tumorigenesis, yet clinical significance and relevance of these genes in breast cancer remains incompletely elucidated. In this study, we performed an integrated multi-database analysis to investigate the roles of BRCA1 and GATA3 in breast cancer. Analysis of multiple datasets revealed high mutation rates in both genes in breast cancer and high expression levels in ER-positive/luminal subtypes cancers relative to those in ER-negative/basal-like tumors. The expression of BRCA1 and GATA3 positively correlated with that of luminal markers but negatively correlated with that of basal-like markers and epithelial-mesenchymal transition transcription factors (EMT-TFs). Survival analyses indicated that high GATA3 expression conferred a favorable prognosis, whereas elevated BRCA1 expression predicted poor survival. This study provides valuable insights into the function and therapeutic implications of BRCA1 and GATA3 in breast cancer.

Keywords

Breast cancer / BRCA1 / GATA3 / Epithelial-mesenchymal transition (EMT)

References

[1] Abdel-Hafiz HA. Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer. Diseases, 2017, 5316.

[2] Adomas AB, Grimm SA, Malone C, et al. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. BMC Cancer, 2014, 14: 278.

[3] Alexandrov LB, Nik-Zainal S, Siu HC, et al. A mutational signature in gastric cancer suggests therapeutic strategies. Nature Communications, 2015, 2968683.

[4] Ali A, Christie PT, Grigorieva IV, et al. Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Human Molecular Genetics, 2007, 16326575.

[5] Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiology, Biomarkers & Prevention, 2004, 1310155868.

[6] Anczuków O, Ware MD, Buisson M, et al. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?. Human Mutation, 2008, 2916573.

[7] Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology, 2007, 922019.

[8] Asselin-Labat ML, Sutherland KD, Vaillant F, et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Molecular and Cellular Biology, 2011, 3122460922.

[9] Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Current Opinion in Genetics & Development, 2002, 1218691.

[10] Bai F, Chan HL, Scott A, et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Research, 2004, 7421616172.

[11] Bai F, Liu S, Liu X, et al. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors. Breast Cancer Research, 2021, 23110.

[12] Bai F, Smith MD, Chan HL, et al. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. Oncogene, 2013, 3222271525.

[13] Bai F, Wang C, Liu X, et al. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway. Cell Death & Disease, 2022, 133195.

[14] Bai F, Zhang LH, Liu X, et al. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer. Theranostics, 2021, 111782188233.

[15] Bai F, Zheng C, Liu X, et al. Loss of function of GATA3 induces basal-like mammary tumors. Theranostics, 2022, 122720733.

[16] Belguise K, Guo S, Sonenshein GE. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Research, 2007, 6712576370.

[17] Bernardo GM, Lozada KL, Miedler JD, et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development, 2010, 13712204554.

[18] Bernholtz S, Laitman Y, Kaufman B, et al. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation. Breast Cancer Research and Treatment, 2011, 129255763.

[19] Botuyan MV, Nominé Y, Yu X, et al. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure, 2004, 127113746.

[20] Brzovic PS, Rajagopal P, Hoyt DW, et al. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nature Structural Biology, 2001, 8108337.

[21] Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genetics, 2006, 3811128997.

[22] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discover, 2012, 254014.

[23] Chen D, Gervai JZ, Póti Á, et al. BRCA1 deficiency specific base substitution mutagenesis is dependent on translesion synthesis and regulated by 53BP1. Nature Communications, 2022, 131226.

[24] Chen F, Chandrashekar DS, Varambally S, et al. cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications, 2019, 1015679.

[25] Chou J, Lin JH, Brenot A, et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature Cell Biology, 2013, 15220113.

[26] Copson Ellen R, Maishman Tom C, Tapper Will J, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. The Lancet Oncology, 2018, 192169180.

[27] Dydensborg AB, Rose AA, Wilson BJ, et al. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene, 2009, 2829263442.

[28] Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. American Journal of Human Genetics, 2007, 81587383.

[29] Eeckhoute J, Keeton EK, Lupien M, et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research, 2007, 6713647783.

[30] Fedele M, Cerchia L, Chiappetta G. The epithelial-to-mesenchymal transition in breast cancer: focus on basal-like carcinomas. Cancers (Basel), 2017, 910134.

[31] Figueiredo JC, Haile RW, Bernstein L, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: The WECARE study. Breast Cancer Research and Treatment, 2010, 120117583.

[32] Findlay GM, Daza RM, Martin B, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature, 2018, 5627726217222.

[33] Foo TK, Xia B. BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Research, 2022, 821831913197.

[34] Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science, 1994, 26651821202.

[35] Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical Cancer Research, 2010, 167211521.

[36] Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signal, 2013, 6269pl1.

[37] Gong C, Fujino K, Monteiro LJ, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene, 2015, 3439501224.

[38] Gong C, Yao S, Gomes AR, et al. KOHBRA study group; Khoo US, Lam EW. BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis, 2016, 54e214.

[39] Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut, 2007, 5656015.

[40] Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Research and Treatment, 2010, 123372531.

[41] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144564674.

[42] Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: Essential functions before and after T-helper-2-cell differentiation. Nature Reviews Immunology, 2009, 9212535.

[43] Hosokawa H, Tanaka T, Kato M, et al. Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression. Proceedings of National Academy of Science U S A, 2013, 110461862631.

[44] Hruschka N, Kalisz M, Subijana M, et al. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene, 2020, 393254555467.

[45] Jézéquel P, Campone M, Gouraud W, et al. Bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Research and Treatment, 2012, 131376575.

[46] Jézéquel P, Gouraud W, Ben Azzouz F, et al. bc-GenExMiner 45: new mining module computes breast cancer differential gene expression analyses. Database (Oxford), 2021, 2021: baab007.

[47] Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology, 2006, 379121726.

[48] Kim R, Yu J, Lim J, et al. Whole-genome landscapes of 1,364 breast cancers. Nature, 2025.

[49] Ko LJ, Yamamoto M, Leonard MW, et al. Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-cell receptor delta gene enhancer. Molecular and Cellular Biology, 1991, 115277884

[50] Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 487: 330-7.

[51] Kouros-Mehr H, Bechis SK, Slorach EM, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell, 2008, 13214152.

[52] Kouros-Mehr H, Kim JW, Bechis SK, et al. GATA-3 and the regulation of the mammary luminal cell fate. Current Opinion in Cell Biology, 2008, 20216470.

[53] Kouros-Mehr H, Slorach EM, Sternlicht MD, et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 2006, 1275104155.

[54] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 2017, 3172324022416.

[55] Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of National Academy of Science U S A, 2008, 105516805.

[56] Liu X, Bai F, Wang Y, et al. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis. Cell Death & Disease, 2023, 146370.

[57] Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of National Academy of Sciences U S A, 2007, 10429121116.

[58] Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathology, 2006, 19226471.

[59] Mair B, Konopka T, Kerzendorfer C, et al. Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity. PLoS Genetics, 2016, 12: e1006279.

[60] Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994, 26651826671.

[61] Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell, 2010, 7340317.

[62] Moreno M, Oliveira JS, Brianese RC, et al. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer. Cancer Medicine, 2023.

[63] Oster Flayshman S, Hidmi O, Alva-Ornelas JA, et al. The breakome of BRCA1 and BRCA2 pathway mutation carriers reveals early processes in breast oncogenesis. Cell Death & Disease, 2025, 161891.

[64] Pandolfi PP, Roth ME, Karis A, et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nature Genetics, 1995, 111404.

[65] Pei XH, Bai F, Smith MD, et al. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell, 2009, 155389401.

[66] Pereira B, Chin SF, Rueda OM, et al. Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 6711908.

[67] Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene, 2003, 2237578491. 1;

[68] Proia TA, Keller PJ, Gupta PB, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell, 2011, 8214963.

[69] Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews Cancer, 2011, 1216878.

[70] Saotome M, Poduval DB, Nair R, et al. GATA3 truncation mutants alter EMT related gene expression via partial motif recognition in luminal breast cancer cells. Frontiers in genetics, 2022, 2813820532.

[71] Schrijver LH, Olsson H, Phillips KA, et al. Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectrum, 2018, 22023.

[72] Scott A, Bai F, Chan HL, et al. p16 loss rescues functional decline of Brca1-deficient mammary stem cells. Cell Cycle, 2017, 168759764.

[73] Sengodan SK, Sreelatha KH, Nadhan R, et al. Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer. Critical Reviews in Oncology/Hematology, 2018, 123: 74-82.

[74] Shakya R, Reid LJ, Reczek CR, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science, 2011, 33460555258.

[75] Singh AK, Yu X. Tissue-specific carcinogens as soil to seed BRCA1/2-mutant hereditary cancers. Trends Cance, 2020, 67559568.

[76] Sjöstedt E, Zhong W, Fagerberg L, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science, 2020, 3676482eaay5947.

[77] Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Research, 2010, 705211525.

[78] Stone A, Zotenko E, Locke WJ, et al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nature Communications, 2015, 1467758.

[79] Takaku M, Grimm SA, Roberts JD, et al. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nature Communications, 2018, 911059.

[80] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 2017, 45W1W98W102.

[81] Tkocz D, Crawford NT, Buckley NE, et al. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene, 2012, 3132366778.

[82] Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nature Reviews Cancer, 2004, 4108149.

[83] U.S. Cancer Statistics Working Group. (2012). United States Cancer Statistics: 1999-2008 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Available from: http://www.cdc.gov/uscs.

[84] Usary J, Llaca V, Karaca G, et al. Mutation of GATA3 in human breast tumors. Oncogene, 2004, 2346766978.

[85] Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature, 2000, 406679441922.

[86] Visvader JE, Stingl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes & Development, 2014, 2811114358.

[87] Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science, 2013, 3396127154658.

[88] Wang C, Bai F, Zhang LH, et al. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression. Breast Cancer Research, 2018, 20174.

[89] Wang H, Bierie B, Li AG, et al. BRCA1/FANCD2/BRG1-driven DNA repair stabilizes the differentiation state of human mammary epithelial cells. Molecular Cell, 2016, 632277292.

[90] Wang H, Xiang D, Liu B, et al. Inadequate DNA damage repair promotes mammary transdifferentiation, leading to BRCA1 breast cancer. Cell, 2019, 1781135151.e19.

[91] Wang X, Bai F, Liu X, et al. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer. BMC Biology, 2024, 22185.

[92] Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378655978992.

[93] World Health Organization. (2012). Breast cancer: prevention and control. Available from: http://www.who.int/cancer/detection/breastcancer/en/index.html.

[94] Yan W, Cao QJ, Arenas RB, et al. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. Journal of Biological Chemistry, 2010, 285181404251.

[95] Ye X, Tam WL, Shibue T, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature, 2015, 525756825660.

[96] Yu X, Chini CC, He M, et al. The BRCT domain is a phospho-protein binding domain. Science, 2003, 302564563942.

[97] Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature, 2009, 4597245460463.

[98] Zhu X, Shan L, Wang F, et al. Hypermethylation of BRCA1 gene: Implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 150347986.

Funding

National Natural Science Foundation of China(82504025)

Shenzhen Medical Research Fund(A2402021)

Shenzhen Natural Science Foundation-The Stable Support Program(20220810144854005)

Shenzhen Science and Technology Program(JCYJ20250604182652069)

Guangdong Basic and Applied Basic Research Foundation(2025A1515010107)

The Program for Youzuzhikeyan of Shenzhen University(SZU2024YZZKY002)

Rights & permissions

Shenzhen University Medical School